Successful HTA Submissions with Proven Expertise and Strategy

We have extensive experience delivering successful HTA submissions across the globe. Our HTA experience spans from orphan indications to crowded oncology markets, and we have delivered successful HTA submissions, in-house and in collaboration with trusted partners across Europe, Asia, the Americas and Australasia.
Build your RFP

What makes us different

Our HTA success is built on an insight-driven Pricing & Market Access strategy, including robust economic modelling and considering all markets and perspectives.
We provide seamless continuity between strategy development, evidence synthesis and reimbursement submissions ensuring optimised launch success.
We give our clients a distinct advantage by leveraging our extensive knowledge and understanding of best practices gained through over 90+ successful HTA submissions in the UK and Ireland. We don't just complete applications – we guide them, support them, and empower them to achieve their goals.
  • By tailoring submissions to reflect HTA guidelines, FIECON build clear and robust clinical and cost-effectiveness cases.
  • Knowledge of the unwritten rules - HTA bodies have public guidelines, and FIECON has insights on how these are implemented on a day-to-day basis; knowing where you can push the boundaries can make a huge difference.
  • Patient and clinician engagement is a major factor in an successful HTA outcome; an essential FICON step is to engage with KOLs and patient groups throughout the submission process.
  • A key to the success of our HTA submissions is being prepared with robust argumentation and proactively responding to objections during pivotal Committee meetings.
Meet our HTA experts
Lisa Cox
Executive Director
Sabine Gaugris
Executive Director
Romita Das
Associate Director
Our team has delivered:

150+

Global HTA submissions

96%

Success rate NICE submissions

95%

Success rate SMC  submissions

100%

Success rate NCPE

Our strategic solutions

Our integrated teams combine expert knowledge in health economics, mathematics, statistics, data science, and therapeutic experience to deliver practical solutions that balance technical requirements with practical application. We maximise outcomes to help achieve commercial success in a highly competitive landscape.
Get in touch

Everything you always wanted to know about JCA

What is JCA?  Is my product eligible? The Joint Clinical Assessment (JCA) for oncology, haematology, and ATMPs will be eligible for assessment from January 12th, 2025 with two significant updates this month.
Read more

Respecting the technical, delivering the practical

Our integrated teams combine extensive knowledge in health economics, mathematics, statistics, data science, and therapeutic experience to deliver practical solutions that balance technical requirements with practical applications.
  • HTA scientific advice (NICE, SMC,NCPE, EMA-EUnetHTA, CADTH)
  • HTA and reimbursement submissions
  • Mock HTA panels
  • Evidence package critical appraisals
  • Post-submission support
  • Rapid scientific advice
  • Reimbursement trackers and management applications

Get in touch

Get a completely free, no-obligation opportunity to discuss your needs and see how we can boost your business.
  • Brainstorm solutions to key challenges with experienced team
  • Validate your strategy and value evidence
  • Learn more about FIECON’s products and key areas of expertise and discuss opportunities for collaboration

Your contact details

I would like to
By submitting this form, you confirm that you agree to our website terms of use

Thank you!

We received your details. Someone from our team will contact you soon.
Oops!
Something went wrong while submitting the form.